Titanium Media App March 31 news, atomization technology company Smore International (06969. HK) released its 2021 annual results report, with annual operating income of RMB13.755 billion (the same below), an increase of 37.4% year-on-year, and adjusted earnings per share of RMB0.91.
According to the financial report, last year, Simar launched a new generation of automated production lines independently developed to realize the automated production of assembly, liquid injection, packaging and other full production lines, and its single-line production efficiency can reach 7200 standard atomizers per hour, which has exceeded the industry level and taken the lead in large-scale application to core customers.
In addition, the revenue of TO B business for enterprise customers exceeded 10 billion yuan for the first time last year, at 12.59 billion yuan, an increase of 37.4% year-on-year; the revenue of TO C business for retail customers was 1.16 billion yuan, an increase of 37.1% year-on-year.
In the overall financial report of 2021, the cost of Simmer for research and development increased by nearly 60%, at present, its cumulative patent application is 3408, covering four types of technology such as temperature control, heating element, anti-leakage liquid, and liquid storage, and last year, there were 1187 new patent applications worldwide, an increase of 60% over the previous year, the vast majority of which are around the "atomized CPU" ceramic atomization core technology.
In terms of the proportion of specific investment, in 2021, Smol's investment in research and development expenses was 670 million yuan, an increase of 59.7% year-on-year. The main R&D investment focuses on cutting-edge materials science, fluid mechanics, aerodynamics, thermodynamics and other fields.
Among them, 7 basic science research institutes established in China and the United States have been put into operation. By the end of 2021, Smore has 1254 R&D personnel, including 101 doctors and above, an increase of 47% and 215% respectively over last year.
According to Sullivan's relevant report, in 2021, Smol's share of the global market share continued to expand, reaching 22.8%, exceeding the sum of the second to fifth places. The report also pointed out that the global electronic atomization equipment market size will grow rapidly in the next 5 years, with a compound growth rate of 24.6%. However, the report from Zhiyan Consulting pointed out that the share of atomization products by 2024 is only 9.3%.
To this end, Smore plans to achieve a full category layout of atomized products in 2022. At the same time, Smore will also enter the one-time category overseas in 2022. According to the financial report, Smore will also carry out new exploration and layout in the field of medical treatment and beauty, and is cooperating with well-known teams at home and abroad to develop medical, beauty and other related products, which is expected to be soon introduced to the market.
After the meeting, the titanium media App interviewed the senior management of Smol, in the face of the new policy of the "E-cigarette Management Measures" to be implemented on May 1, Simos believes that the new policy restricts multi-flavor products, plus the current user preference for tobacco-flavored products is different, which is bound to have a certain impact on the Chinese market.
However, for overseas markets such as Europe and the United States, multi-flavor products are still the mainstream, and Smore remains optimistic about its overseas market business. In 2023 and beyond, as users in the domestic market get used to tobacco-flavored products, the domestic related market of Smore will surely rebound.
In addition, Smore also said that the taste laboratory previously established will not stagnate. For the global market, we will continue to develop multi-flavor products to ensure our share of the global market. For the domestic market, the focus is on the development of tobacco-flavored products and continuous improvement.
When talking about the application of other scenarios in addition to the electronic atomizer, Simar also revealed that the current research and development direction is not only in the field of medical nebulizers, the goal is to develop pharmaceutical combination products, nebulizers have been studied for 2 years, and now the atomization agents have also made breakthroughs. For nebulizers in other fields, the three directions of medical, health and beauty have been laid out. (This article was first published on titanium media App)